Document is current
Any future updates will be listed below
-
Authors
Yoshida, Chikashi
Kondo, Takeshi
Ito, Tomoki
Kizaki, Masahiro
Yamamoto, Kazuhiko
Miyamoto, Toshihiro
Morita, Yasuyoshi
Eto, Tetsuya
Katsuoka, Yuna
Takezako, Naoki
Uoshima, Nobuhiko
Imada, Kazunori
Ando, Jun
Komeno, Takuya
Mori, Akio
Ishikawa, Yuichi
Satake, Atsushi
Watanabe, Junichi
Kawakami, Yoshiko
Morita, Tetsuo
Taneike, Ikue
Nakayama, Masahiko
Duan, Yinghui
Garbayo Guijarro, Belen
Delgado, Alexander
Llamas, Cynthia
Kiyoi, Hitoshi
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 16 November 2021
Revised: 15 March 2022
Accepted: 15 March 2022
First Online: 8 April 2022
Declarations
:
: C. Yoshida: Investigator on AbbVie-funded clinical study. Honoraria from Bristol Myers Squibb, Novartis Pharma KK, Pfizer Japan Inc., Otsuka Pharmaceutical., AbbVie, Janssen Pharmaceutical KK, Nippon Shinyaku Co., Ltd., Chugai Pharmaceutical Co., Ltd. Research funding from Bristol Myers Squibb. T. Kondo: Advisory role for Astellas Pharma, Otsuka Pharmaceutical. Honoraria from Astellas Pharma, Bristol Myers Squibb, Otsuka Pharmaceutical, Novartis, and Sumitomo Dainippon Pharma. T. Ito: Research funding from AbbVie and Bristol Myers Squibb. Honoraria from AbbVie, Bristol Myers Squibb, Takeda Pharmaceutical Sanofi, CSL Behring, and Novartis. M. Kizaki, Y. Morita, T. Eto, Y. Katsuoka, N. Takezako, N. Uoshima, J. Ando, A. Mori, A. Satake, J. Watanabe: No potential conflicts of interest are reported. K. Yamamoto, T. Komeno: Investigator on AbbVie-funded clinical study. T. Miyamoto: Honoraria from AbbVie, Astellas Pharmaceutical, Astellas Amgen Pharmaceutical, Bristol Myers Squibb, Celgene, Merck Sharp & Dohme, Otsuka Pharmaceutical, and Takeda Pharmaceutical. K. Imada: Honoraria from Astellas Pharma, Bristol Myers Squibb, Celgene, Chugai Pharmaceutical, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis, Otsuka Pharmaceutical, and Takeda Pharmaceutical. Y. Ishikawa: Personal fees from AbbVie, Astellas Pharma, Chugai Pharmaceutical, Daiichi-Sankyo, FUJIFILM, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis, and Pfizer. Y. Kawakami, T. Morita, I. Taneike, M. Nakayama, Y. Duan, B. Garbayo Guijarro, A. Delgado, C. Llamas: Employees of AbbVie and may hold stock or options. H. Kiyoi: Research funding from AbbVie, Astellas Pharma, Bristol Myers Squibb, Chugai Pharmaceutical, CURED Inc., Daiichi Sankyo, Eisai, FUJIFILM, Kyowa Hakko Kirin, Nippon Shinyaku, Novartis, Otsuka Pharmaceutical, Perseus Proteomics, Pfizer, Sanofi, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, and Zenyaku Kogyo. Honoraria from Astellas Pharma, Bristol Myers Squibb, and Novartis.
